Lipopharma presents the last results of the clinical trial with 2OHOA at BIO-Europe 2014

Print

Palma de Mallorca, November 04th, 2014. Lipopharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with 2OHOA for the treatment of glioma and other solid tumours. The presentation was in the Next Generation track and the main results of the first 5 cohorts in the MIN-001-1203 study have been presented. No safety issues have arisen at doses of up to 8g/day while clinical benefit has been reported in two patients, one of then in a GBM patient showing a sustained Partial Response after more than 1 year of continued treatment.

 

Prof. X. Busquets, president of Lipopharma's SAB, and Vicenç Tur, CEO, at the BioEurope 2014 event.

Supported by


                 

 

 

Financiado por el Ministerio de Economía y Competitividad. Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011. Subprograma INNCORPORA 2011 (INC-TU-2011-1007)

© 2017 Lipopharma | legal notice Copyright 2011 Lipopharma - Lipopharma presents the last results of the clinical trial with 2OHOA at BIO-Europe 2014. All Rights Reserved.
Joomla 1.7 templates by hostgator coupon and learn how to make a website